Drug Patents owned by Impel Neuropharma
1. List of Trudhesa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9550036 | IMPEL NEUROPHARMA | Nasal drug delivery device |
Sep, 2032
(9 years from now) | |
| US10507295 | IMPEL NEUROPHARMA | Nasal drug delivery device |
Dec, 2032
(9 years from now) | |
| US10940278 | IMPEL NEUROPHARMA | Nozzles for nasal drug delivery |
Jan, 2033
(9 years from now) | |
| US9919117 | IMPEL NEUROPHARMA | Nozzles for nasal drug delivery |
Mar, 2033
(9 years from now) | |
| US11266799 | IMPEL NEUROPHARMA | In-line nasal delivery device |
Nov, 2036
(13 years from now) | |
| US11185497 | IMPEL NEUROPHARMA | Intranasal delivery of dihydroergotamine by precision olfactory device |
Jan, 2039
(15 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | Sep 2, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
More Information on Dosage
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic